麦澜德（688273）：女性健康业务加速拓展，积极布局脑机业务

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Viewpoints - The company is accelerating its expansion in women's health and actively laying out its brain-machine interface business [5] - The company focuses on pelvic floor rehabilitation and aims to meet the full lifecycle treatment needs of women [6] - The brain-machine interface market is projected to grow significantly, with a compound annual growth rate of 17.4% from 2025 to 2034 [7] - The company has made strategic investments in various health and beauty sectors, establishing a foundation for long-term growth [6][8] Summary by Relevant Sections Market Performance - The closing price of the company is 28.88 yuan, with a total market value of 2,888 million yuan and a circulating market value of 1,063.56 million yuan [3] Financial Forecast and Valuation - The company is expected to achieve revenues of 4.23 billion, 5.27 billion, and 6.69 billion yuan for the years 2024, 2025, and 2026, respectively, with year-on-year growth rates of 24.02%, 24.65%, and 27.01% [9][11] - The projected net profit attributable to the parent company for the same years is 1.02 billion, 1.30 billion, and 1.69 billion yuan, with growth rates of 13.75%, 27.51%, and 30.08% [9][11] - The current price-to-earnings ratio (PE) is projected to be 28, 22, and 17 for the years 2024, 2025, and 2026, respectively [9][11] Investment Logic - The company is well-positioned to benefit from the low penetration rate of pelvic floor and postpartum rehabilitation products in the domestic market [13] - The company is expanding into aesthetic medicine and sports rehabilitation, leveraging AI and brain-machine interface technologies for long-term revenue contributions [13] Key Assumptions - Revenue growth for pelvic floor and postpartum rehabilitation devices is expected to be 19.00%, 18.00%, and 18.00% from 2024 to 2026 [12] - Revenue growth for consumables and accessories is projected at 10.00%, 14.00%, and 18.50% for the same period [12] - The reproductive rehabilitation segment is anticipated to grow significantly, with expected growth rates of 74.60%, 55.00%, and 52.00% [12]